


Ifw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application. No. : 10/713,578  
 First Named Inventor : Sanjay Awasthi  
 Filing Date : November 13, 2003  
 Title : LIPOSOMES FOR PROTECTION AGAINST TOXIC ORGANIC COMPOUNDS  
 Group Art Unit : 1641  
 Examiner : not yet assigned

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope, with sufficient postage, addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 this 13 day of October, 2005.

Mail Stop: Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

*Stella E. Laicer*

Signature

Stella E. Laicer

Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the references set forth in the attached form PTO/SB/08A. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. A copy of each non-patent reference is enclosed herewith.

It is requested that the Examiner fully consider the cited referenced and that it be cited on the front of any patent issuing from this application.

An early action on the merits is respectfully requested.

Respectfully submitted,


Date: Oct 13, 2005

*Monique A. Vander Molen*

Monique A. Vander Molen

Registration No. 53,716

Gardere Wynne Sewell LLP  
 1601 Elm Street, Suite 3000  
 Dallas, Texas 75201-4761  
 214-999-3000

 Substitute for 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary) Sheet <u>1</u> of <u>2</u>	<b>Complete If Known</b>	
	Application Number	10/714,578
	Filing Date	November 13, 2003
	First Named Inventor	Sanjay Awasthi
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Attorney Docket Number	124263-1006

NON PATENT LITERATURE DOCUMENTS			T <sup>2</sup>
Examiner Initial*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		Sanjay Awasthi et al, Biochemistry, 37:5231-5238 (1998)	
		Sanjay Awasthi et al, Biochemistry, 37:5239-5248 (1998)	
		Sanjay Awasthi et al, Biochemistry, 39:9327-9334 (2000)	
		Ji-Zhong Cheng et al, Journal of Biological Chemistry, 276(44):41213-41223 (2001)	
		Yusong Yang et al, Journal of Biological Chemistry, 274(44): 19920-19230 (2001)	
		Sanjay Awasthi et al, Biochemistry, 40:4159-4168 (2001)	
		Sanjay Awasthi et al, Drug Metabolism and Disposition, 30(12):1200-1210 (2002)	
		Sharad S. Singhal et al, International Journal of Oncology, 22:365-375 (2003)	
		Sanjay Awasthi et al, International Journal of Oncology, 22:713-720 (2003)	
		Sanjay Awasthi et al, International Journal of Oncology, 22:721-732 (2003)	
		Sanjay Awasthi et al, International Journal of Cancer, 106(5):635-646 (2003)	
		Rajendra Sharma et al, International Journal of Cancer, 112:934-942 (2004)	
		Sanjay Awasthi et al, Cancer Research, 65(14):6022-6028 (2005)	
Examiner Signature			Date Considered

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional.). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2*

Substitute for 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>  Sheet <u>2</u> of <u>2</u>	<b>Complete If Known</b>	
	Application Number	10/714,578
	Filing Date	November 13, 2003
	First Named Inventor	Sanjay Awasthi
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Attorney Docket Number	124263-1006

NON PATENT LITERATURE DOCUMENTS			T <sup>2</sup>
Examiner Initial*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		David Stuckler et al, Cancer Research, 65(3):991-998 (2005)	
		Sushma Yadav et al, Biochemical and Biophysical Research Communications, 328:1003-1009 (2005)	
		Sharad S. Singhal et al, Biochemical Pharmacology, 70:481-488 (2005)	
		Rajendra Sharma et al, Archives of Biochemistry and Biophysics 391(2):171-179 (2001)	
		Abstract: Sanjay Awasthi et al, RLIP 76 Mediates Doxorubicin Transport and Resistance in Lung Cancer, 18 <sup>th</sup> Annual Meeting of the International Society for Biological Therapy of Cancer (ISBTC), Bethesda, MD, October 30 – November 2, 2003	
		Abstract: S. Awasthi et al, Anti-RLIP76 Antibodies Induce Apoptosis and Enhance Doxorubicin Cytotoxicity in Lung Cancer Cells, American Association for Cancer Research, 92 <sup>nd</sup> Annual Meeting, New Orleans, LA, March 24-28, 2001	
		Abstract: Sanjay Awasthi et al, Anti-RLIP76 Antibodies Induce Apoptosis in Lung Cancer Cells and Display Marked Synergy with Doxorubicin, American Association for Cancer Research, 93 <sup>rd</sup> Annual Meeting, San Francisco, CA, April 6-10, 2002	
		Abstract: S. Awasthi et al, Tyrphostin and Genistein Inhibit ATPase and transport activity of RLIP76 and increase doxorubicin toxicity in lung cancer cells, American Association of Cancer Research, 94 <sup>th</sup> Annual Meeting, Washington, DC, July 11-14, 2003	
		Abstract: S. Awasthi et al, RALPB1 is a major determinant of radiation sensitivity and glutathione-Conjugate transport, American Association for Cancer Research, 95 <sup>th</sup> Annual Meeting, Orlando, FL, March 27-31, 2004	
		Abstract: Dilki Wickramarachchi et al, Identification of Membrane Anchoring Domains of RLIP76 Using Deletion Mutant Analysis, American Association of Cancer Research, 96 <sup>th</sup> Annual Meeting Anaheim, CA, April 16-20, 2005	
Examiner Signature			Date Considered

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2*